Abstract:Objective: Tumor metastasis is a complex, multistep process that depends on tumor cells and their communication with the tumor microenvironment. A p53 gain-of-function mutant has been shown to enhance the tumorigenesis, invasion, and metastasis abilities of tumor cells. This study aimed to investigate the roles of p53 R273H mutation in the tumor microenvironment. Methods: The in vitro and in vivo effects of the p53 R273H mutant on the invasion and metastasis of HCT116 cells were investigated. Exosomes from wild-type and HCT116-TP53(R273H) cells were cocultured with mouse embryonic fibroblasts (MEFs). The roles of differentially expressed exosomal microRNAs identified by microarray analysis were investigated. The functions of the p53 R273H mutant in tumor cells were also investigated via gene expression microarray and quantitative polymerase chain reaction (qPCR) analyses. Results: Introducing p53 R273H mutant into HCT116 cells significantly potentiated pulmonary metastasis in vivo. In the presence of exosomes derived from HCT116-TP53(R273H) cells, the exosomes were taken up by MEFs and became activated. Microarray analysis showed that the p53 R273H mutation increased the exosomal levels of miR-21-3p and miR-769-3p. Intriguingly, in clinical samples, miR-21-3p and miR-769-3p levels were significantly higher in patients with a p53 mutation than in those without this mutation. Furthermore, both miR-21-3p and miR-769-3p activated fibroblasts and exerted a synergistic effect via their target genes on the transforming growth factor-beta (TGF-beta)/Smad signaling pathway. The activated fibroblasts excreted cytokine TGF-beta and may have reciprocally induced cancer cells to undergo epithelial-mesenchymal transition (EMT). Indeed, HCT116-TP53(R273H) cells showed increased expression of ZEB1 and SNAI2 and decreased transcription of several cell adhesion molecules. Conclusions: The mutant p53-exosomal miR-21-3p/miR-769-3p-fibroblast-cytokine circuit appears to be responsible for communication between tumor and stromal cells, with exosomal miRNAs acting as a bridge. miR-21-3p and miR-769-3p are potential predictive markers of pulmonary metastasis and candidate targets for therapeutic interventions.

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

The tumor suppressor p53 regulates autophagosomal and lysosomal biogenesis in lung cancer cells by targeting transcription factor EB.

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

P53 Mutation and Deletion Contribute to Tumor Immune Evasion

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Mutant p53-Mediated Tumor Secretome: Bridging Tumor Cells and Stromal Cells

Mutant P53 Drives Cancer Metastasis Via RCP-Mediated Hsp90α Secretion.

Differential Regulation of the REGγ–proteasome Pathway by P53/tgf-Β Signalling and Mutant P53 in Cancer Cells

Mutant p53 increases exosome-mediated transfer of miR-21-3p and miR-769-3p to promote pulmonary metastasis.

Pharmacological Activation of the P53 Pathway Within the Tumor Microenvironment Induces Immunogenic Cell Death of Tumors and Enhances Antitumor Immunity

p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Targeting mutant p53 stabilization for cancer therapy

Differential Regulation Of The Reg Gamma-Proteasome Pathway By P53/Tgf-Beta Signalling And Mutant P53 In Cancer Cells

p53 missense mutant G242A subverts natural killer cells in sheltering mouse breast cancer cells against immune rejection

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications